5-Amino-1MQ: NNMT Inhibition and the NAD+ Pathway

Most of what sits in a research-compound catalogue is peptide: a chain of amino acids that finds a receptor or a binding partner and does its work through that association. 5-Amino-1MQ is not a peptide and does not work that way. It is a small heterocyclic molecule carrying a permanent positive charge, and its reported activity comes from occupying the active site of a single enzyme and blocking one methyl-transfer reaction. That distinction governs almost everything downstream: how it behaves in an assay, how it is stored, and how its purity is properly established.

This article summarises what the published literature reports: its chemistry, the enzyme it inhibits, the findings described in cell and rodent models, the pharmacokinetic data that exist, and the analytical and handling considerations relevant to its use as a laboratory reference material. Every finding below is drawn from in vitro work or from studies in mice and rats. Nothing here describes use outside those settings.

Chemistry and identity

5-Amino-1MQ is the common shorthand for 5-amino-1-methylquinolinium, which also appears in the primary literature as 5-AMQ and 5A1MQ. The cation has the molecular formula C₁₀H₁₁N₂⁺ and a molecular weight of 159.21 (PubChem CID 950107). Structurally it is a quinoline ring with a methyl group quaternising the ring nitrogen and a primary amine at the 5-position.

That quaternised nitrogen is the defining feature. Because the positive charge is permanent rather than pH-dependent, the compound cannot exist as a neutral free base; it is always supplied as a salt, most commonly the iodide (C₁₀H₁₁IN₂, molecular weight 286.11, PubChem CID 66522933).

This has a practical consequence that is easy to miss. Slightly more than 44 per cent of the mass of the iodide salt is counter-ion. A milligram of salt is not a milligram of active cation, and a molarity calculated from gross vial weight without correcting for salt form will be overstated by roughly a factor of 1.8. Any certificate of analysis for a quaternary ammonium compound should state the salt form explicitly.

The enzyme: nicotinamide N-methyltransferase

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine. It is expressed at high levels in liver, and its expression in white adipose tissue and skeletal muscle varies substantially with metabolic state.

The reason this single reaction has attracted sustained interest is that it consumes two metabolically expensive currencies at once. Nicotinamide is the precursor that feeds the NAD⁺ salvage pathway, so every molecule NNMT methylates is one withdrawn from that pool. SAM is the universal methyl donor for the cell, so every reaction also consumes one unit of methylation capacity. Elevated NNMT activity has therefore been proposed as a simultaneous drain on NAD⁺ availability and on methyl-group supply.

The observational literature is consistent with that framing. Metabolomic surveys reported a correlation between urinary 1-MNA and body mass index (Salek et al., 2007), and Kannt and colleagues (2015) reported upregulated NNMT expression in the white adipose tissue of insulin-resistant individuals, with plasma 1-MNA correlating with both the degree of insulin resistance and adipose NNMT expression.

Genetic manipulation in animals provided the more direct evidence. Kraus and colleagues (Nature, 2014) reported that antisense knockdown of NNMT in white adipose tissue and liver reduced relative adiposity in diet-induced obese mice by approximately 47 per cent. Hong and colleagues (2015) reported that reducing NNMT expression in primary hepatocytes lowered glucose output by roughly half, while overexpression raised it around 1.4-fold, with the effect appearing to run through Sirt1.

Selectivity and membrane permeability

The foundational pharmacological characterisation of the methylquinolinium series was published by Neelakantan, Vance, Wetzel, Wang, McHardy, Finnerty, Hommel and Watowich in Biochemical Pharmacology (2018, volume 147, pages 141–152). Two of its findings are the reason 5-Amino-1MQ became the reference compound for this class.

The first is permeability. NNMT is cytosolic, so an inhibitor has to cross the plasma membrane before it can reach its target — a non-trivial requirement for a permanently charged cation. Using parallel artificial membrane permeability assays and Caco-2 monolayers, the authors reported that methylquinolinium scaffolds bearing primary amine substitutions showed high permeability by both passive and active transport.

The second is selectivity. The compounds were tested against structurally related SAM-dependent methyltransferases and against enzymes of the NAD⁺ salvage pathway, and did not inhibit them. For a molecule intended as a mechanistic probe, that matters more than potency: an inhibitor that also blocks neighbouring methyltransferases produces results that cannot be attributed to NNMT. In cultured adipocytes, the same study reported that NNMT inhibition reduced intracellular 1-MNA, raised intracellular NAD⁺ and SAM, and suppressed lipogenesis — all three measurements moving in the directions the mechanistic model predicts.

Findings in metabolic models

In diet-induced obese mice maintained on a high-fat diet, systemic administration of a potent NNMT inhibitor was reported to significantly reduce body weight and white adipose mass, decrease adipocyte size, and lower plasma total cholesterol. The authors noted that treatment did not alter total food intake and that no adverse effects were observed. The food-intake result is the mechanistically informative one: it argues that the observed change in the animals reflects altered energy utilisation rather than suppressed appetite.

Subsequent work examined the compound alongside dietary intervention. Sampson and colleagues (Scientific Reports, 2021) combined NNMT inhibitor treatment with a lean diet substitution in diet-induced obese mice and reported accelerated body weight and fat loss, an increased ratio of lean mass to body weight, and reduced liver and epididymal white adipose tissue weights relative to the diet substitution alone. Body composition and liver adiposity in the combination group were reported to normalise to the levels seen in age-matched lean-diet controls.

The most recent characterisation of 5-Amino-1MQ specifically comes from Babula, Bui, Stevenson, Watowich and Neelakantan (Diabetes, Obesity and Metabolism, 2024, volume 26, pages 5272–5282), who administered the compound once daily for 28 days to diet-induced obese mice and reported dose-dependent limitation of body weight and fat mass gains and improved oral glucose tolerance, alongside plasma and tissue pharmacokinetics after intravenous, oral and subcutaneous dosing.

Aged skeletal muscle

A separate line of work concerns muscle rather than adipose tissue. Neelakantan and colleagues (Biochemical Pharmacology, 2019) reported that systemic NNMT inhibitor administration to aged mice was associated with elevated muscle stem cell proliferation and fusion, supporting nearly two-fold greater myofibre cross-sectional area following injury and a shift in fibre size distribution towards larger fibres. Peak torque of the tibialis anterior was reported as roughly 70 per cent greater in treated animals than in controls.

Dimet-Wiley and colleagues (Scientific Reports, 2024, volume 14, article 15554) extended this by treating 22-to-24-month-old mice with an NNMT inhibitor, intensive exercise, or both, comparing grip strength, running capacity, plantarflexor peak torque, fatigue and fibre cross-sectional area across the groups. The design is notable because it tests whether the compound's reported effect is redundant with exercise or additive to it — a question single-intervention studies cannot address.

Pharmacokinetics in rodents

Awosemo, Neelakantan, Watowich, Ma, Wu, Chow and Liang (Journal of Pharmaceutical and Biomedical Analysis, 2021, volume 204, article 114255) developed and validated an LC-MS/MS assay for 5-AMQ in rat plasma and urine, and applied it to a pharmacokinetic study. The method detail is directly useful to anyone quantifying the compound: extraction by protein precipitation, separation on a C18 column (2 µm, 50 × 2.1 mm) with a water/acetonitrile gradient containing 0.1 per cent formic acid, and multiple reaction monitoring in positive mode at the m/z transition 159.100 → 90.00. Standard curves were linear from 10 to 2500 ng/mL, with precision and accuracy within 15 per cent and extraction recoveries of 99.5 to 110.6 per cent.

In rats, the compound showed a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean terminal elimination half-lives of 3.80 ± 1.10 hours intravenously and 6.90 ± 1.20 hours orally, and oral bioavailability of 38.4 per cent. That last figure is higher than a permanently charged quaternary cation would naively be expected to achieve, and is consistent with the active-transport component described in the earlier Caco-2 work.

Laboratory handling

Handling a quaternary ammonium salt differs from handling a lyophilised peptide in several ways, and applying peptide habits uncritically leads to avoidable losses.

• Light and the counter-ion. Iodide is photosensitive and oxidises to iodine on exposure to light and air, presenting as yellow-to-brown discolouration of a material that should be pale. Amber vials or foil are worth the effort, and the discolouration is a visible integrity signal that peptides do not offer.
• The aromatic amine. The 5-amino group is susceptible to oxidation, particularly in solution and at elevated pH. Working solutions are better prepared fresh, or aliquoted and frozen, than stored and repeatedly accessed.
• Solubility. The charged cation is water-soluble and aqueous stocks are straightforward. Where DMSO is used for cell work, its hygroscopicity is the usual confounder — water uptake shifts the nominal stock concentration over time.
• Salt correction. Calculate molarity from the cation mass and the stated salt form, not from gross weight.
• Solid storage. Desiccated, at −20 °C, protected from light. The broader principles are set out in our guide to peptide storage and handling, most of which transfers.

Analytical verification

Because 5-Amino-1MQ is not a peptide, the conventions used to report peptide purity do not map onto it cleanly. There is no net peptide content to report, though the salt-form question is analogous to the counter-ion correction applied to a TFA-salt peptide.

Purity is appropriately established by HPLC with UV detection — the quinolinium chromophore absorbs strongly, so sensitivity is not the limiting factor — with identity confirmed by mass spectrometry. One point deserves attention. Because the analyte is a pre-formed cation, electrospray ionisation produces the [M]⁺ ion directly at m/z 159, not the [M+H]⁺ ion at m/z 160 that an analyst accustomed to neutral molecules might look for; the 159 → 90 transition used in the validated rat plasma assay reflects exactly this. A spectrum reported against the wrong expected mass is a recurring source of confusion with quaternary compounds.

A complete characterisation package would also address counter-ion identity and content, residual synthesis solvents, and water content, none of which a chromatographic purity percentage captures. Third-party analytical documentation for our catalogue is published on the Lab Results page.

What remains unresolved

The most significant open question is attribution. NNMT inhibition simultaneously raises NAD⁺, raises SAM, and lowers 1-MNA, and the 2018 work measured all three moving together. Which of them drives the reported physiological outcomes — or in what combination — has not been separated experimentally. This is complicated by the fact that 1-MNA is not an inert waste product; it has reported signalling activity of its own, so reducing it is not a purely subtractive intervention.

Two further limits apply to extrapolation. NNMT expression varies widely between tissues and species, so results from one model do not transfer confidently to another. And the entire evidence base summarised above is preclinical: there are no published human clinical trial data for 5-Amino-1MQ itself. Every finding described here was observed in cell culture, in mice, or in rats.

For laboratories working with the compound as a mechanistic probe, that combination is what makes it useful: a small, chemically stable molecule with a demonstrated selectivity profile and a validated bioanalytical method behind it, addressing an enzyme whose role in cellular energy metabolism is established but whose downstream consequences are still being mapped. Researchers examining metabolic regulation from a different angle may find our overview of MOTS-c a useful comparison.

Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.